Kornimate/medical-research-clean huggingface dataset:
acute effects of inorganic nitrite on cardiovascular hemodynamics in heart failure with preserved ejection fraction

Conditions: Heart Disease; Heart Failure With Preserved Ejection Fraction; Exercise Intolerance; Pulmonary Hypertension

Summary: heart failure with preserved ejection fraction (hfpef) is a major public health problem that has no proven effective treatment. this study assessed the effects of acute nitrite administration on resting and exercise hemodynamics in patients with hfpef.

subjects were studied on their long-term medications in the post-absorptive state and supine position. right heart catheterization was performed with simultaneous expired gas analysis at rest and during supine exercise at a 20 watts workload for 5 minutes. after the first exercise phase (before any drug administration) and after return to steady-state baseline hemodynamic values, subjects were randomized. study drug or placebo was infused for 5 minutes. after a 10 minute observation period, hemodynamic measurements were repeated at rest, followed by repeat supine exercise at a 20 watts workload for 5 minutes, identical to the study's first phase. arterial and venous blood samples and hemodynamic and expired gas data were acquired during each stage of the protocol.

Eligibility criteria:
inclusion criteria: * scheduled to undergo a cardiac catheterization procedure. * clinical symptoms of shortness of breath and fatigue * normal left ventricular ejection fraction (≥50%) * elevated left ventricular filling pressures at cardiac catheterization (defined as resting pulmonary capillary wedge pressure (pcwp)\>15 mmhg and/or pcwp≥25 mmhg during exercise) exclusion criteria: * systolic bp \<120 mmhg * prior nitrate therapy (within previous 2 weeks) * glucose 6-phosphate dehydrogenase (g6pd) deficiency * other "non-hfpef" specific causes of heart failure such as significant valvular disease (\>moderate left-sided regurgitation, \>mild stenosis), severe pulmonary disease, unstable coronary disease or coronary spasm, primary renal or hepatic disease, constrictive pericarditis, or infiltrative, restrictive, or hypertrophic cardiomyopathies
prednisone-placebo vs prednisone-valacyclovir in bell´s palsy

Conditions: Bell´s Palsy

Summary: since steroids carry a moderate beneficial effect in bell's palsy, and to address this question, valacyclovir was added to prednisone for the treatment of this condition.

between december 2002 and december 2003, a total of 52 subjects with bp were evaluated, 42 fulfilled the inclusion criteria and entered the study, 1 patient was lost to follow-up after the first visit, leaving a total of 41 patients with complete clinical follow-up. to be included in the study, patients had to be evaluated within the first 72 hours and could have no contraindications to steroid or valacyclovir therapy. patients were randomly assigned to either the prednisone-valacyclovir (group 1) or the prednisone-placebo group (group 2) among the 41 patients completing the study, 19 pertenecian al group 1 and 21 group 2 both groups received prednisone, a dose of 1 mg/kg body weight was given daily for 7 days (one single dose after breakfast). the treatment was tapered over the next 14 days. those taking valacyclovir received 1000 mg in two daily doses for 7 days. all subjects were instructed about eye protection and lubrication were followed at regular intervals until recovery or for a minimum period of 3 months. follow-up included examination at 1, 2, 4, 8 and 12 weeks after the first visit. patients with incomplete recovery at 3 months were controlled until complete recovery or stabilization of the paralysis. all subjects were evaluated for laboratories parameters. routine blood count, blood sugar, and liver function tests were performed at first visit. there were no severe side effects attributable to the valacyclovir-prednisone treatment in this study. informed consent was obtained from all patients. facial nerve function was assessed using the facial grading system (fgs) the scale used provides a quantitative score with three components; resting symmetry, symmetry of voluntary movement and synkinesis and a composite score was obtained. student's t-test was employed for quantitative....variables. comparison of treatment results between both groups was performed by....means of an analysis of variance (anova) test of two ways (therapy and time). all statistical tests were considered received the same level of significance (p = 0.05).

Eligibility criteria:
inclusion criteria: * patients with bell´s palsy evaluated within the first 72 hours. exclusion criteria: * peptic ulcer * tuberculosis * moderate or severe diabetes * moderate or severe hypertension * glaucoma * manifest cardiac disease * psychosis * renal or hepatic dysfunction, and * pregnancy.

Keywords: bell´s palsy prednisone valacyclovir
imaging retinal vasculature in infant eyes

Conditions: Retinopathy of Prematurity

Summary: retinopathy of prematurity is a leading cause of childhood blindness worldwide. the fovea, a critical location in the retina determining visual acuity and visual function, and the blood vessels around it, are abnormally developed in infants with retinopathy of prematurity. however, how these blood vessels form during development of the human fovea remains unclear. this research will advance our understanding of the fundamental knowledge of how the blood vessels around the fovea form in infants, and how they change in diseased states such as preterm birth or retinopathy of prematurity.


Eligibility criteria:
inclusion criteria: * health care provider, knowledgeable of protocol, agrees that study personnel could contact the parent/legal guardian * parent/legal guardian is able and willing to consent to study participation for the infant * infant meets the american association of pediatrics eligibility of rop screening, and is age less than 34 6/7 weeks postmenstrual age at first visit exclusion criteria: * participant or parent/legal guardian unwilling or unable to provide consent * infant has a health or eye condition that preclude eye examination or retinal imaging (e.g. corneal opacity such as with peter's anomaly or cataract) * infant has a health condition, other than prematurity, that has a profound impact on brain development (e.g. anencephaly)

Keywords: retinopathy of prematurity optical coherence tomography perifoveal vasculature vascular development macular edema rop oct prematurity optical coherence tomography angiography octa
hoosier sport: developing and implementing a sustainable campus-community partnership in rural indiana

Conditions: Cardiovascular Diseases; Sedentary Behavior

Summary: the clinical trial aims to develop and pilot test a multilevel physical activity (pa) intervention called the hoosier sport program. the study follows a participatory co-design protocol involving youth, parents, and community leaders to provide direct input into the intervention's design. the ultimate goal is to contribute to health equity in the community by promoting sustainable physical activity. hoosier sport involves delivering enhanced physical education classes, teaching about nutrition and exercise, as well as developing leadership skills in middle school rural students.the intervention will last for 8-weeks with pe classes occur twice a week. additionally, hoosier sport will create more opportunities for students to be active at school (e.g., in home room) through providing virtual classes and other activities.


Eligibility criteria:
inclusion criteria: * has pe class the semester during hoosier sport- * parent provides informed consent exclusion criteria: * answer yes to any question on the physical activity readiness for everybody (parq+)
pericapsular nerve group block in hip arthroplasty

Conditions: Post Operative Pain After Hip Arthroplasty

Summary: peripheral nerve blocks are becoming increasingly popular for hip surgery anesthesia. modern regional anesthesia for major hip surgery includes the use of a single shot and continuous epidural or spinal injections, continuous lumbar plexus blockade and continuous peripheral blockade of the femoral nerve (fn), fascia iliaca (fi) block, 3-in-1 fn block and sciatic nerve. the use of either single shot or continuous peripheral nerve blocks are becoming increasingly popular. this study will be conducted to evaluate the effect of ultrasound guided pericapsular nerve group block in hip arthroplasty surgery.

hip joint is richly innervated, and the pain following hip arthroplasty is particularly severe. effective postoperative analgesic technique especially in an elderly with significant comorbidities is challenging. (1) peripheral nerve blocks are becoming increasingly popular for hip surgery anesthesia. modern regional anesthesia for major hip surgery includes the use of a single shot and continuous epidural or spinal injections, continuous lumbar plexus blockade and continuous peripheral blockade of the femoral nerve (fn), fascia iliaca (fi) block, 3-in-1 fn block and sciatic nerve. the use of either single shot or continuous peripheral nerve blocks are becoming increasingly popular. (2) these techniques have shown effective and safe postoperative pain control, resulting in lower opioid consumption, improved earlier rehabilitation and high patient satisfaction. (3) pericapsular nerve group (peng) block has been recently recommended by giron-arango et al. for use as postoperative analgesia in hip surgeries. it is a new regional anesthesia method based on blocking the articular branches of femoral nerve (fn) and accessory obturator nerve(aon) and obturator nerve in the region between the anterior inferior iliac spine (aiis) and ilio-pubic eminence (ipe).the anterior capsule is the most richly innervated section of the joint suggesting these nerves should be the main targets for hip analgesia. (4)

Eligibility criteria:
inclusion criteria: * patients will involve in the research if they will schedule for unilateral hip arthroplasty (tha) surgery. * aged more than 50 years of both genders. * have american society of anesthiologists physical status i-ii and iii. exclusion criteria: * revision hip arthroplasty. * hip arthroplasty. combined with subtrochanteric shortening osteotomy. * drug allergy. * regular narcotic use. * renal \&/ or hepatic impairments. * coagulopathy disorders.
a study to learn about study medicine alta2618 in adults with akt1 e17k-mutant solid tumors

Conditions: Cancer; Breast Cancer; Endometrial Cancer; Metastatic Cancer; Advanced Solid Tumor

Summary: the purpose of this study is to characterize the safety and tolerability of alta2618 in adults with akt1 e17k-mutant advanced solid tumors.

this is an open-label, multicenter, phase 1/1b study of alta2618, a mutant-selective and orally bioavailable akt1 e17k inhibitor, in adults with akt1 e17k-mutant solid tumors. this study will evaluate the safety, tolerability, pharmacokinetics (pk), and preliminary clinical activity of alta2618, and aims to find the best dose. the study consists of two parts: part 1 - dose escalation and part 1b - dose expansion.

Eligibility criteria:
inclusion criteria: * histologically confirmed diagnosis of a solid tumor malignancy harboring akt1 e17k mutation identified through molecular testing (ngs- or pcr-based) with a clinical laboratory improvement amendments-certified (or equivalent) diagnostic test. * unresectable or metastatic disease * progressed on, intolerant to, or declined prior standard-of-care therapy (including targeted therapy, if applicable) appropriate to tumor type and stage * evaluable or measurable disease per recist v1.1 * eastern cooperative oncology group (ecog) performance status of 0 or 1. * adequate organ function. exclusion criteria: * prior treatment with pi3k and/or mtor inhibitors * patients known to have kras, nras, hras, or braf genomic alterations in their tumor * known condition that prohibits ability to swallow or absorb an oral medication other inclusion/exclusion criteria may apply.

Keywords: akt1 e17k breast cancer breast carcinoma breast neoplasm er positive breast hr positive breast triple negative breast cancer gynecologic cancer gynecologic neoplasm gynecologic carcinoma endometrial cancer endometrial neoplasm endometrial carcinoma cervical cancer cervical neoplasm cervical carcinoma ovarian cancer ovarian carcinoma ovarian neoplasm fallopian cancer fallopian carcinoma fallopian neoplasm prostate cancer prostate carcinoma prostate neoplasm solid tumors akt mutation mutant akt akt1 mutation akt mutant akt1e17k
detecting circulating tumor cells (ctcs) and cell free dna (cfdna) in peripheral blood of breast cancer (bc) patients to develop the clinical application for early detection and diagnostics

Conditions: Breast Cancer

Summary: utilization of circulating-tumor-cell (ctc) and cell free dna (cfdna) as novel and noninvasive tests for diagnosis confirmation, therapy selection, and cancer surveillance is a rapidly growing area of interest. in the wake of fda approval of a liquid biopsy test, it is important for clinicians to acknowledge the obvious clinical utility of liquid biopsy for cancer management throughout the course of the disease.


Eligibility criteria:
inclusion criteria: * all subjects need to sign the informed consent form and age is above 20. * control group need to have mammogram /ultrasound results category1-3 and confirmed by pi. * cancer group subjects with pathology report confirmed to be malignant have not yet done surgery or treatment will be enrolled to the malignant group for analysis exclusion criteria: * not willing to sign the informed consent form * have been undergone general anesthesia or regional anesthesia in 1 month * have been diagnosed with any type of cancer and been treated * have been suffering from autoimmune disorder such as sle and ra * have been suffering from chronic infection such as ibd, pancreatitis, copd or interstitial pneumonia. * have been suffering from acute infection or other infectious diseases in 3 moths such as tb, pneumonia, urinary tract infection, or cellular infection * diagnosed with myelodysplastic syndrome or myeloproliferative diseases * other condition which may affect the ctc results, when determined by pi can be confirmed by other tests are if necessary

Keywords: breast cancer. circulating tumor cells. ctcs. cell free dna. cfdna
ym598 added to mitoxantrone/prednisone to control pain in metastatic prostate cancer patients no longer responding to hormone therapy

Conditions: Hormone-Refractory Prostate Cancer; Prostatic Neoplasms

Summary: the purpose of this study is to determine if patients who take ym598 in addition to mitoxantrone and prednisone (standard therapy) experience improvement in the pain associated with prostate cancer metastases in the bone.


Eligibility criteria:

Keywords: androgen-independent prostate cancer
main branch versus side branch ostial lesion

Conditions: Coronary Artery Stenosis

Summary: the investigators studied the relations between coronary angiography (cag), intravascular ultrasound (ivus) and fractional flow reserve (ffr) in coronary ostial lesions.

angiographic evaluation for ostial lesions is reported to be inaccurate in the assessment of the functional and clinical significance of a lesion. the investigators studied the relations between coronary angiography (cag), intravascular ultrasound (ivus) and fractional flow reserve (ffr) in coronary ostial lesions.

Eligibility criteria:
inclusion criteria: * age 21-85 * presence of at least one obstructive coronary artery stenosis at coronary ostium as defined by: * previous catheterization with any coronary ostium lesion 50% or greater * ability and willingness to provide informed consent * ability and willingness to perform required follow up procedures exclusion criteria: * history of coronary artery bypass graft surgery * left main coronary ostial lesion * significant stenosis at proximal or distal part of coronary ostium lesion * ostial lesion related to infarcton * creatinine\>1.6 mg/dl or gfr\<30 pre-procedure per institutional standards * ejection fraction lower than 40% * known pregnancy * arrhythmia * contrast agent allergy that cannot be adequately premedicated * patient not a candidate for ivus and ffr * inability or unwillingness to provide informed consent * inability or unwillingness to perform required follow up procedures

Keywords: ffr ivus qca
sideritis supplementation, oxidative stress and health

Conditions: Oxidative Stress; Lipidemia

Summary: the aim of the present clinical study is to estimate the efficacy of a sideritis scardica extract (sidtea+), derived from the greek mountain taygetos, in regulating antioxidant and health biomarkers in healthy adults.

introduction: the mountain tea of genus sideritis has more than 150 species, which are mainly distributed in the mediterranean area. in the literature, extensive reference is made to the secondary metabolites of sideritis, the main ones of which are terpenoids (i.e., iridoids and kauranes) and phenolic derivatives (i.e., flavonoids, phenolic acids, phenylethanoid glycosides). polyphenols exhibit a wide range of biological activities, such as anti-atherogenic, anti-cancer, anti-mutagenic, anti-inflammatory and antimicrobial properties. among phenolic derivatives, major significance is given to flavonoids, due to their antioxidant, anti-inflammatory, antibacterial, antiviral and anti-allergic properties in various pathologies. flavonoids mainly act as antioxidants, inhibiting free radical-induced cytotoxicity and lipid peroxidation. moreover, these compounds are known to inhibit tumor growth and proliferation and act as weak agonists or antagonists of estrogens by regulating endogenous hormonal activity. in these ways, they can protect against chronic diseases such as atherosclerosis and cancer and regulate menopausal symptoms. purpose: this study aims to investigate the effect of a sideritis scardica extract (sidtea+) supplement from the greek mountain taygetos on health and oxidative stress indicators in healthy individuals. the results of the present investigation will help to elucidate the effects of an extract derived from a plant product on markers of health and oxidative stress in apparently healthy individuals. methodology: 30 healthy individuals will be enrolled in the study. participants will give their informed consent after they will be informed about the purposes, procedures, risks and benefits associated with the study. participants will be randomly allocated to either a sideritis spp or a placebo supplementation group and they will consume 1500 mg/day of sideritis or placebo, distributed in three equal doses (every 8 hours) for one month. at baseline and post-intervention, volunteers will be assessed for their anthropometric profile, muscle function and cardiorespiratory capacity and will provide a resting blood sample for the assessment of oxidative stress and health biomarkers. participants will be asked to record their diet for 3 days prior to the study and they will be asked to follow the same dietary pattern for 3 days before the post-intervention assessments.

Eligibility criteria:
inclusion criteria: * healthy individuals aged 18-65 years exclusion criteria: * musculoskeletal injury * dietary supplements * medication

Keywords: sideritis extract antioxidants oxidative stress health
super-selective intraarterial intracranial infusion of bevacizumab (avastin) for glioblastoma multiforme

Conditions: Glioblastoma Multiforme

Summary: the high-grade malignant brain tumor glioblastoma multiforme (gbm) comprise the majority of all primary brain tumors in adults. this group of tumors also exhibits the most aggressive behavior, resulting in median overall survival durations of only 9-12 months for gbm. initial therapy consists of surgical resection, external beam radiation or both. currently, all patients experience a recurrence after this first-line therapy, so improvements in both first-line and salvage therapy are critical to enhancing quality-of-life and prolonging survival. superselective intraarterial cerebral infusion (siaci) is a technique that can effectively increase the concentration of drug delivered to the brain while sparing the body of systemic side effects. this technique threads a tiny catheter through the patient's femoral artery in the leg, up through the body and neck and into the brain. once the catheter reaches the brain, chemotherapy is released to the blood vessels that feed the tumor.


Eligibility criteria:
inclusion criteria: * histologically confirmed diagnosis of gbm * grade iv gbm tumors that have recurred after total resection * age \> 18 years * at least four weeks following any recent surgery * patients must have a karnofsky performance status ≥60% and an expected survival of ≥ three months. * no iv chemotherapy for three weeks prior to treatment under this research protocol and no external beam radiation for four weeks prior to treatment under this research protocol. * patients must have adequate hematologic reserve * pre-enrollment coagulation parameters (pt and ptt) must be adequate. * patients must agree to use a medically effective method of contraception during and for a period of three months after the treatment period. a pregnancy test will be performed on each premenopausal female of childbearing potential immediately prior to entry into the research study. * patients must be able to understand and give written informed consent. informed consent must be obtained at the time of patient screening. exclusion criteria: * women who are pregnant or lactating. * women of childbearing potential and fertile men will be informed as to the potential risk of procreation while participating in this research trial and will be advised that they must use effective contraception during and for a period of three months after the treatment period. * patients with significant intercurrent medical or psychiatric conditions that would place them at increased risk or affect their ability to receive or comply with treatment or post-treatment clinical monitoring.
drug-drug interaction study in healthy subjects

Conditions: Hepatitis C

Summary: the purpose of this study is to assess the pharmacokinetics and safety of bms-790052 and bms-650032 when co-administered and when administered alone

pharmacokinetics and safety in healthy subjects

Eligibility criteria:
inclusion criteria: * healthy male and female subjects aged 18 to 49 years * females who are not of childbearing potential, pregnant or breastfeeding * subject body mass index (bmi) of 18 to 32 kg/m² exclusion criteria: * women of child bearing potential * male subjects who have sex with women who are unwilling to agree to practice male barrier contraception during study participation and for a least 12 weeks following dosing * any significant acute or chronic medical illness * evidence of organ dysfunction or any clinically significant deviation from normal in physical examination, vital signs, ecg or clinical laboratory determinations * prior exposure to bms-650032 or bms-790052 * positive for hiv or hcv